Manulife Singapore has teamed up with Guardant Health to improve access to the cutting-edge Guardant360 liquid biopsy test for eligible customers with advanced solid tumour cancers. This landmark collaboration represents a significant step in advancing cancer care in Singapore, offering patients access to personalised treatment options that may enhance clinical outcomes.
The Guardant360 liquid biopsy test provides comprehensive genomic profiling for all advanced solid tumours. It offers critical genomic and epigenomic insights from a simple blood draw, delivering results within just seven days of lab sample receipt. This non-invasive test is especially valuable for patients who lack sufficient tumour tissue for traditional biopsies, helping oncologists quickly identify appropriate treatments.
While specific eligibility criteria and program details will be announced later, this initiative promises to provide Manulife customers with broader access to guideline-recommended biomarkers across all solid cancers.
This is such an important initiative! Early cancer detection and better access to care can truly save lives, and it’s great to see companies like Manulife and Guardant Health working together to make a difference. Advancements like these give hope for more accessible and effective treatments in the future. I’ve been struggling with my essays lately before I found https://forum.aresearchguide.com/threads/help-me-find-the-best-essay-writing-service-failed-my-midterm-essay.3/ discussion where I shared my experience of failing my midterm essay, and was recommneded a real help online. It is just a wake-up call.